Amylyx Pharmaceuticals has pivoted from its prior ALS commercial product following unsuccessful trials to focus on a pipeline addressing rare endocrine and neurodegenerative diseases. Its lead candidate, avexitide, is in a Phase 3 trial for post-bariatric hypoglycemia and congenital hyperinsulinism, with topline data anticipated in Q3 2026. The company continues clinical development of AMX0035 and AMX0114. Despite a revenue increase in 2023 tied to legacy product sales, Amylyx remains unprofitable with significant operating losses and negative cash flows, supported by substantial cash reserves but reliant on continued capital for development and commercialization.